Estimates Revisions Madrigal Pharmaceuticals, Inc.
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 26/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 516.56 USD | +0.65% |
|
-2.81% | -11.30% |
| 09-24 | Analyst recommendations: Dropbox, Etsy, Meta Platforms, Okta, Rollins… |  |
| 09-23 | Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- MDGL Stock
- Consensus Madrigal Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
